As a pioneer in cancer immunotherapy, Ono Pharmaceutical Co.,Ltd. takes advantage of its experience, technology and knowhow, nurtured through R&D of the immune checkpoint inhibitor OPDIVO, toward discovering innovative anticancer drugs beyond OPDIVO.

Building on decades of continuous research experience and accumulated expertise in immunology that contributed to the discovery of Opdivo, Ono Pharmaceutical Co., Ltd. has established a Research Center for Immunology.  At this center, drug discovery efforts focus on immune mediated inflammatory diseases with significant unmet medical needs, leveraging optimal modalities tailored to each therapeutic target.

In the Neurology area, Ono Pharmaceutical Co.,Ltd. is prioritizing its research in biology of Glial cells, which maintain and support the environment necessary for survival and functional expression of neurons. Drug discovery based on human evidence would bring patients disease-modifying therapies, as well as symptomatic treatments for neurodegenerative disease, mental illness or chronic pain.